The stock of Acrivon Therapeutics Inc (ACRV) has seen a 20.90% increase in the past week, with a 1.36% gain in the past month, and a -16.23% decrease in the past quarter. The volatility ratio for the week is 7.80%, and the volatility levels for the past 30 days are at 7.86% for ACRV. The simple moving average for the last 20 days is 16.79% for ACRV’s stock, with a simple moving average of -10.05% for the last 200 days.
Is It Worth Investing in Acrivon Therapeutics Inc (NASDAQ: ACRV) Right Now?
Company’s 36-month beta value is 0.79.Analysts have differing opinions on the stock, with 6 analysts rating it as a “buy,” 5 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ACRV is 21.96M, and currently, short sellers hold a 5.31% ratio of that floaft. The average trading volume of ACRV on February 05, 2025 was 49.21K shares.
ACRV) stock’s latest price update
Acrivon Therapeutics Inc (NASDAQ: ACRV)’s stock price has gone rise by 13.54 in comparison to its previous close of 5.91, however, the company has experienced a 20.90% increase in its stock price over the last five trading days. seekingalpha.com reported 2024-12-12 that Acrivon Therapeutics is developing a targeted oncology therapy with a companion proteomics-based signature, showing promising activity in their lead compound for certain patients with gynecologic cancers. The pipeline updates indicate progress in clinical trials, enhancing the potential for successful outcomes in targeted cancer treatments. Financially, Acrivon is well-positioned with sufficient funding to advance its pipeline, though risks remain inherent in biotech investments.
Analysts’ Opinion of ACRV
Ladenburg Thalmann, on the other hand, stated in their research note that they expect to see ACRV reach a price target of $16. The rating they have provided for ACRV stocks is “Buy” according to the report published on September 16th, 2024.
ACRV Trading at 5.99% from the 50-Day Moving Average
After a stumble in the market that brought ACRV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -43.61% of loss for the given period.
Volatility was left at 7.86%, however, over the last 30 days, the volatility rate increased by 7.80%, as shares surge +7.81% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +12.62% upper at present.
During the last 5 trading sessions, ACRV rose by +31.89%, which changed the moving average for the period of 200-days by -30.55% in comparison to the 20-day moving average, which settled at $5.78. In addition, Acrivon Therapeutics Inc saw 11.46% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ACRV starting from PERCEPTIVE ADVISORS LLC, who purchase 2,353,000 shares at the price of $8.50 back on Apr 11 ’24. After this action, PERCEPTIVE ADVISORS LLC now owns 5,360,858 shares of Acrivon Therapeutics Inc, valued at $20,000,500 using the latest closing price.
Stock Fundamentals for ACRV
Current profitability levels for the company are sitting at:
- -45.27 for the present operating margin
- 0.7 for the gross margin
The net margin for Acrivon Therapeutics Inc stands at -40.86. The total capital return value is set at -0.43. Equity return is now at value -45.95, with -42.09 for asset returns.
Based on Acrivon Therapeutics Inc (ACRV), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -15.12. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -52.11.
Currently, EBITDA for the company is -59.85 million with net debt to EBITDA at 0.46. When we switch over and look at the enterprise to sales, we see a ratio of 89.4. The liquidity ratio also appears to be rather interesting for investors as it stands at 12.75.
Conclusion
In a nutshell, Acrivon Therapeutics Inc (ACRV) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
